ALS News Today Home | ALS News Today
网页2024年10月1日 · Immune proteins activation at ALS diagnosis linked to progression. Researchers detected changes in the production of several immune signaling proteins, called cytokines, in the cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord — of people with amyotrophic lateral sclerosis (ALS) at diagnosis.
Immune proteins activation at ALS diagnosis linked to progression
网页4 天之前 · These changes also correlated with certain clinical characteristics, and how quickly the disease progressed. “Inflammatory activation [is] present in ALS at the time of diagnosis and may characterize patients at higher risk for disease progression,” the researchers wrote.
Mayo Clinic granted $22M to study ibudilast in ALS patient program
网页2024年9月30日 · ALS is a progressive neurological disorder marked by dysfunction and death of motor neurons, the specialized nerve cells that facilitate movement, speaking, swallowing, and breathing.Its hallmark symptom is muscle weakness, which typically affects one part of the body at first, then spreads to other regions and becomes more severe.. Most patients first experience weakness in the hand or feet ...
Target ALS, Modality.AI partner to study AI in ALS
网页5 天之前 · The trial will harness a virtual, conversational AI system, called Tina, intended to detect even the smallest changes in ALS symptoms.. Five clinical sites, all part of the Target ALS Global Natural History Study, are recruiting 150 ALS patients and 50 healthy participants, who will serve as controls.Two participants have so far been enrolled in the study, which is taking place in Spanish- as ...
Clene granted in-person FDA meeting on CNM-Au8 for ALS
网页2024年9月24日 · Clene has been granted an in-person meeting with the U.S. Food and Drug Administration (FDA) — to be held before the end of November, according to the company — to discuss a potential accelerated approval of CNM-Au8 as a treatment for amyotrophic lateral sclerosis (ALS). Under such a pathway ...
Early 2024 eyed for approval decision in EU on masitinib for ALS
网页2023年9月22日 · Final results from the trial demonstrated that treatment with a 4.5 mg/kg dose of masitinib for nearly one year significantly slowed disease progression — by 27% — in people with a so-called normal disease progression. Specifically, that means a monthly decline in the ALS Functional Rating Scale-Revised scores of less than 1.1 points.
What is Amyotrophic Lateral Sclerosis (ALS)? | ALS News Today
网页2023年3月20日 · ALS diagnosis. No single test can diagnose ALS. The diagnostic workup for the disease broadly involves assessments that check for ALS-like damage to motor neurons and confirmation of ALS disease progression, combined with tests to rule out other potential causes for the symptoms. It usually takes about a year from the time symptoms first appear until the diagnosis of ALS is confirmed.
Phase 1 clinical trial of experimental ALS therapy AKV9 to soon...
网页2023年8月28日 · Combining AKV9 with the approved ALS therapies riluzole (sold as Rilutek, among others) and edaravone (sold as Radicava and Radicava ORS) led to even greater improvements in upper motor neuron health in additional experiments in a similar mouse model. The therapy can also cross the blood-brain barrier, a highly selective membrane that regulates which substances can access the brain and spinal ...
ALS Disease Progression Slowed With Low-dose Aldesleukin: Trial
网页2022年12月16日 · A pivotal Phase 2 clinical trial called IMODALS (NCT02059759) investigated the effects of low-dose aldesleukin injections in 36 people with ALS. Results showed that three months of treatment significantly increased the number and activity of Tregs compared with a placebo.. Effects of low-dose aldesleukin in MIROCALS
Top 10 ALS Stories of 2021 - ALS News Today
网页2022年1月3日 · In late March, we reported that a Phase 3 clinical trial was recruiting ALS patients to evaluate the safety and effectiveness of NeuroNata-R (lenzumestrocel), a stem cell therapy conditionally approved to treat ALS in South Korea. The ALSummit trial (NCT04745299), which was approved by the FDA and is still recruiting participants, aims to enroll about 115 patients in South Korea to support a ...